Glow Protocol

Glow Protocol is described as a three-component peptide blend. GHK-Cu is the copper-binding tripeptide in the stack and is linked in the source to collagen, elastin, glycosaminoglycan production, matrix metalloproteinase modulation, and angiogenesis signals from cell and animal evidence. BPC-157 is included for proposed pro-healing and anti-inflammatory activity tied to angiogenesis and growth-factor signaling in rodent studies. TB-500 is described as an actin-binding thymosin beta-4 fragment included for cell migration and tissue-remodeling hypotheses. The source explicitly frames the combined mechanism as plausible extrapolation rather than proof that the injectable blend works as a unified product.

The source distinguishes the evidence for the ingredients. GHK-Cu is described as having the strongest human support, but specifically from topical cosmetic studies rather than injectable Glow Protocol use; reported topical outcomes include reduced wrinkle depth and better skin density and firmness across 8 to 12 weeks. A gene-profiling analysis is also cited as finding broad GHK associations with wound-repair and inflammation-related human genes, but the source characterizes that as computational rather than direct clinical evidence. BPC-157 and TB-500 are described as remaining in the animal-data category without completed human efficacy trials. The source further states that the injected GLOW blend has no published trial of its own, so topical GHK-Cu results should not be assumed to apply to the injectable three-peptide blend. It also flags injection of copper peptides as a risk area not addressed by topical studies.